Skip to content

PSMA PET-guided precision radiotherapy for prostate cancer

PSMA PET-guided precision radiotherapy for prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108852
Enrollment
Unknown
Registered
2025-09-08
Start date
2023-03-24
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Case series:NA

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult males over 18 years of age; 2. Histopathologically confirmed prostate cancer; 3. Perfect PSMA PET scan prior to enrolment; 4. Eastern Cooperative Oncology Group score (ECOG PS) 0-2; 5. Patients voluntarily agreed to participate in the study and voluntarily signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. The patients with contraindications to functional imaging; 2. The patients with concomitant combination of other anti-tumor therapies or participation in other interventional clinical trials; 3. The patients who cannot comply with the study for psychological, family, or social reasons. 4. Other conditions deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Progression-free survival rate;Dose Response Assessment Model;

Secondary

MeasureTime frame
Detection rate of oligolesions;Results of radiotherapy strategy optimisation;Radiation therapy-associated toxicity;

Countries

China

Contacts

Public ContactYali Shen

Department of Abdominal Oncology, West China Hospital of Sichuan University

sylprecious@163.com+86 189 8060 5780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026